RNTX
Rein Therapeutics Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$0.89
+5.39%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +65.3%
- EBIT
- +14.7%
- EPS
- +31.7%
- Free cash flow
- +11.3%
- Operating cash flow
- +11.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +76.8%
Three-year CAGR
- Revenue
- —
- EBITDA
- -80.3%
- EBIT
- +66.3%
- Net income
- +20.7%
- EPS
- +44.2%
- Free cash flow
- +13.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026